Equipment Trends in Advanced Solid-Dosage Drug Manufacturing: INTERPHEX Keynote Part 3
Fernando Muzzio, PhD, Distinguished Professor of Chemical and Biochemical Engineering at Rutgers University, spoke about trends in continuous manufacturing of OSD drugs.
Equipment and advanced manufacturing approaches to meet the evolving needs for solid-dosage drugs include continuous manufacturing, containment strategies, Industry 4.0 tools, and techniques for optimizing oral solid dosage (OSD) form manufacturing. “Equipment Trends in Advanced Solid-Dosage Drug Manufacturing” was part of a keynote series at INTERPHEX 2021 on Oct. 19, 2021.
The session was moderated by Jennifer Markarian, manufacturing editor, Pharmaceutical Technology, Pharmaceutical Technology Europe, and BioPharm International. In this video, Jennifer interviewed Fernando Muzzio, PhD, Distinguished Professor of Chemical and Biochemical Engineering at Rutgers University about trends in continuous manufacturing of OSD drugs.
This video is part 3 of 5. The other speakers in this session were:
- Part 1: Dave DiProspero, Director Pharmaceutical Process Technology, CRB
- Part 2: Johannes Khinast, PhD, Institute for Process and Particle Engineering in the Research Center Pharmaceutical Engineering (RCPE) at the Graz University of Technology in Austria.
- Part 4: Sharon Nowak, Business Development Manager, Coperion K-Tron USA Food & Pharmaceutical Industries
- Part 5: Gernot Warnke, Head of R&D, JRS Pharma.
Watch other videos in this keynote series:
How Smart Technology is Helping Reach Sustainability Goals in Drug Packaging
June 7th 2025Smart technologies, such as digital and laser printing, incorporated into manufacturing equipment are helping manufacturers align with sustainability goals, according to Sheikh Akbar Ali, general manager and head of Development and Technology for ACG Packaging Materials.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
